blueblock

Rinri has capitalised on its unique deep understanding of auditory biology to build developmentally informed protocols to produce pluripotent cell-derived auditory neurons that match natural cochlear phenotypes and functional physiological characteristics.

Under the right laboratory conditions, we have shown that our progenitor cells are able to mature into functional auditory neuron cells which exhibit the same morphology and electrophysiology as native cells of the inner ear.

Our preclinical studies have clearly demonstrated that when we deliver our cells to the cochlear they survive, engraft, mature and re-establish neural connections to auditory hair cells and wider auditory neural architecture. In models of auditory neuropathy these cells result in a reversal of hearing loss and a 40% improvement in the hearing threshold.

Following our ground-breaking proof of concept data, significant progress has been made to refine and optimise our technology improving yield, efficiency, potency and purity to the levels required to start the pioneering journey towards first in man clinical trials and to ultimately realise the potential of cell therapy for hearing loss.